The fibrates in clinical practice: focus on micronised XXXX .

@entity1 @entity407 @entity3724 @entity3413 @entity301 @entity2299 @entity1674 @entity2453 @entity165
Dietary measures, including calorie restriction and reduced fat intake, remain the mainstay of management in prevention of @entity301 ( @entity301 ). When this fails, drug therapy should be considered. Fibrates, a family of lipid lowering drugs, decrease plasma @entity1674 and inhibit their synthesis. They are also reported to suppress @entity165 production in the liver. A disadvantage of @entity3724 is the poor solubility of the principal ingredient, with subsequent incomplete absorption after oral administration. Micronized @entity3724 , a new formulation chemically identical to the parent compound, has improved pharmacokinetic parameters which increase absorption, provide more stable plasma levels, and thus dosage can be decreased. The micronized formulation has been shown to be effective in reducing LDL @entity165 and @entity1674 in @entity1 with types IIa and IV @entity407 , with increasing responsiveness to therapy in proportion to elevated baseline values of these parameters. This formulation has also been compared to @entity3413 , an @entity2453 reductase inhibitor. Results of a double-blind crossover study showed that both drugs reduced plasma @entity165 levels by similar amounts, and both produced similar increases in HDL @entity165 . The micronized formulation of @entity3724 thus provides improved efficacy in the prevention of @entity301 . In comparison to the standard formulation, micronised @entity3724 thus provides improved efficacy in the control of @entity2299 and the prevention of @entity301 .
